en POLSKI
eISSN: 2083-8441
ISSN: 2081-237X
Pediatric Endocrinology Diabetes and Metabolism
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2023
vol. 29
 
Share:
Share:
abstract:
Editorial

Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us

Alfonso Galderisi
1

  1. Yale University, Department of Pediatrics, New Haven, CT – USA
Pediatr Endocrinol Diabetes Metab 2023; 29 (1): 1-3
Online publish date: 2023/04/11
View full text Get citation
 
PlumX metrics:
The clinical onset of type 1 diabetes (namely stage 3 type 1 diabetes [T1D]) is preceded by a relatively prolonged pre-symptomatic phase featured by islet autoimmunity [1] with (Stage 2 T1D) or without (Stage 1 T1D) dysglycaemia. While islet autoimmunity is the hallmark of the underlying autoimmune process, very little evidence is available for the metabolic changes that accompany the loss of functional beta cell mass. Indeed, a steep decline of C-peptide – a surrogate marker of beta cell function – is measurable only ~6 months before the onset of Stage 3 T1D [2]. Disease modifier drugs have, there-fore, a very limited window of intervention because we lack of effective methods to track beta cell function over time and to identify early changes of insulin secretion that precedes dysglycaemia [3, 4] and clinically symptomatic diabetes.

Herein, we will revise current approaches to longitudinally track beta cell function over time before the onset of Stage 3 T1D, which might be suitable for monitoring the risk for diabetes progression as well as the effectiveness of disease modifier treatments.
keywords:

diabetes mellitus type 1, beta cell, OGTT, CGM, prediabetes


Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.